Zevra Therapeutics, Inc. - Common Stock (NQ:ZVRA)

10.13 +0.14 (+1.40%)

Delayed Quote Updated: 11:58 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zevra Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL

July 11, 2024

Via AB Newswire

FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base ↗

July 09, 2024

FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21.

Via Benzinga

ZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗

May 08, 2024

ZVRA stock results show that Zevra Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) Letter to Stakeholders Looks Like Launch Code to Drive Value

May 06, 2024

Via Investor Brand Network

ZEVRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zevra Therapeutics, Inc. on Behalf of Zevra Stockholders and Encourages Investors to Contact the Firm

April 03, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Zevra Therapeutics: Q4 Earnings Insights ↗

March 28, 2024

Via Benzinga

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zevra Therapeutics, Inc. (ZVRA)

April 02, 2024

From Kirby McInerney LLP

Via GlobeNewswire

ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023 ↗

March 28, 2024

ZVRA stock results show that Zevra Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

Earnings Outlook For Zevra Therapeutics ↗

March 27, 2024

Via Benzinga

Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday ↗

December 28, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Zevra Therapeutics's Earnings: A Preview ↗

November 06, 2023

Via Benzinga

Zevra Therapeutics's Earnings: A Preview ↗

August 11, 2023

Via Benzinga

A Preview Of Zevra Therapeutics's Earnings ↗

May 12, 2023

Via Benzinga

Earnings Preview: Zevra Therapeutics ↗

March 06, 2023

Via Benzinga

Earnings Scheduled For March 28, 2024 ↗

March 28, 2024

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.

Via Benzinga

BioMedNewsBreaks – Zevra Therapeutics Inc. (NASDAQ: ZVRA) Resubmits Arimoclomol New Drug Application to the FDA

December 27, 2023

Via Investor Brand Network

Earnings Scheduled For November 7, 2023 ↗

November 07, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.

Via Benzinga

InvestorNewsBreaks — Zevra Therapeutics Inc. (NASDAQ: ZVRA) Names New President, CEO and Director

October 10, 2023

Via Investor Brand Network

Topics Retirement

Health Care Company Zevra Therapeutics Announces Merger With Acer Therapeutics ↗

August 31, 2023

Via Benzinga

Why Is Acer Therapeutics Stock Trading Higher Today? ↗

August 31, 2023

Zevra Therapeutics Inc (NASDAQ: ZVRA) has agreed to acquire Acer Therapeutics Inc (NASDAQ: ACER) for up to $91 million.

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq -

August 31, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Why Is Acer Therapeutics (ACER) Stock Up 85% Today? ↗

August 31, 2023

Acer Therapeutics (ACER) stock is taking off on Thursday after the company announced an acquisition deal with Zevra Therapeutics (ZVRA).

Via InvestorPlace

Earnings Scheduled For May 15, 2023 ↗

May 15, 2023

Companies Reporting Before The Bell • Caledonia Mining (AMEX:CMCL) is expected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is projected to report earnings for its first quarter.

Via Benzinga

Citius Pharmaceuticals Approaches End Of Trial For Catheter-Related Bloodstream Infections – How Are Analysts Scoring Its Stock? ↗

May 04, 2023

The late-stage biopharma Citius Pharmaceuticals Inc. (NASDAQ: CTXR) is approaching the conclusion of the phase 3 trial for its drug, Mino-Lok.

Via Benzinga

Earnings Scheduled For August 14, 2023 ↗

August 14, 2023

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023 ↗

March 17, 2023

Via Benzinga

Over $7M Bet On This Consumer Defensive Stock? Check Out These 4 Penny Stocks Insiders Are Buying ↗

March 16, 2023

The Dow Jones closed lower by more than 250 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 07, 2023

Via Benzinga

Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 07, 2023

Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the...

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.